NuSynth Raises ₹36.5 Cr Seed Funding Led by Avaana Capital and Shastra VC

Bengaluru-based NuSynth Technologies, a chemical process innovation startup, has raised ₹36.5 crore (approximately $4 million) in a seed funding round co-led by Avaana Capital and Shastra VC.

The startup is developing an AI-powered platform designed to improve chemical synthesis by evaluating raw materials, reaction pathways, and process economics. Its technology aims to help researchers identify alternative chemical production methods with potential improvements in cost, yield, safety, sustainability, and scalability.

The fresh capital will support research and development, technology development, the creation of proprietary chemical processes, scale-up capabilities, and team expansion.

What Does NuSynth Technologies Do?

NuSynth is developing a platform to redesign chemical synthesis processes, which are used to produce chemicals and other materials through controlled reactions.

The company combines predictive synthesis models with an AI engine that processes experimental data to guide subsequent research cycles. Rather than treating each experiment as an isolated activity, the platform is designed to use results from previous experiments to inform future research.

This approach aims to help researchers evaluate alternative synthesis routes and identify processes that may perform better across several parameters, including production costs, yields, safety, environmental impact, and commercial scalability.

According to the company, using historical experimental data to guide research could reduce the time required for chemical research and development.

Initial Focus on Pharmaceuticals and Electronics Chemicals

NuSynth is initially targeting the pharmaceutical and electronics chemicals sectors.

These industries depend on specialized chemical processes, where production economics, material quality, safety, and process consistency can influence commercial viability.

NuSynth plans to develop proprietary chemical processes for commercial applications across multiple chemistry-led industries. Its longer-term strategy is to build a portfolio of processes that can be applied beyond its initial target markets.

The company has not disclosed specific commercial customers, validated performance improvements, or a detailed timeline for bringing its proprietary processes to market in the supplied announcement.

Who Founded NuSynth?

NuSynth was founded by Poorvank Purohit, former managing director and chief executive officer of Solara Active Pharma Sciences, and Dr Ramesha A R, a postdoctoral researcher at the National Institutes of Health in Washington.

The founding team also includes Abhishek Deo and Dipak Bajaj, whose professional experience spans companies including Zetwerk, Mstack, Ola, JPMorgan, BlackBuck, and SUN Mobility.

The team's combination of pharmaceutical industry experience, research expertise, and business and technology backgrounds supports NuSynth's focus on applying AI to chemical process development.

How NuSynth Plans to Use Its Seed Funding

The ₹36.5 crore investment will be directed towards four key priorities:

• Research and development: Strengthening the company's scientific and technical capabilities.

• Proprietary process development: Building an initial portfolio of chemical processes for commercial applications.

• Scale-up capabilities: Improving the ability to advance processes towards larger-scale production.

• Team expansion: Hiring additional talent to support research, engineering, and technology development.

These investments are intended to help NuSynth progress from developing its platform to building chemical processes with potential commercial applications.

Moving from laboratory research to industrial production can require further testing, process optimization, and scale-up work. NuSynth's planned investment in these capabilities reflects the importance of connecting computational research with practical manufacturing requirements.

Why AI-Driven Chemical Synthesis Matters

Chemical research often involves evaluating different raw materials, reaction conditions, and synthesis pathways before researchers can identify a suitable production process.

NuSynth's platform aims to make this work more data-driven by using predictive models and experimental results to inform future research.

The potential benefit is a more systematic way to evaluate alternatives, rather than relying exclusively on repeated experimentation. However, the actual impact will depend on the platform's predictive performance, the quality of available experimental data, and whether proposed processes can be validated and scaled successfully.

For pharmaceutical and electronics chemical manufacturers, improvements in production costs, yields, safety, or sustainability could be commercially valuable. NuSynth is targeting these areas, although the supplied announcement does not quantify the improvements achieved so far.

What Comes Next for NuSynth?

With ₹36.5 crore in seed funding, NuSynth plans to strengthen its technology, expand its team, and develop an initial portfolio of proprietary chemical processes.

Its immediate focus is on pharmaceuticals and electronics chemicals, with ambitions to develop processes for broader chemistry-led industries over time.

The next stage will involve demonstrating that its AI-driven research approach can produce reliable, commercially viable processes beyond the development environment.

For NuSynth, success will depend on turning predictive models and experimental data into measurable improvements in chemical development and production.